ReShape Lifesciences Inc. (RSLS)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue | 1,242 | 1,113 | 2,292 | 1,965 |
| Cost of revenue | 643 | 432 | 853 | 831 |
| Gross profit | 599 | 681 | 1,439 | 1,134 |
| Selling, general and administrative expense | - | - | 719 | 670 |
| Sales and marketing | 583 | 529 | - | - |
| Research and development | 476 | 364 | 399 | 399 |
| General and administrative | 1,591 | 1,627 | 2,082 | 2,119 |
| Transaction costs | 711 | 367 | - | - |
| Total operating expenses | 3,361 | 2,887 | 3,200 | 3,188 |
| Operating loss | -2,762 | -2,206 | -1,761 | -2,054 |
| Interest (income) expense, net | 18 | -40 | - | 4 |
| (gain) loss on foreign currency exchange, net | 61 | -12 | 50 | -16 |
| Loss (gain) on changes in fair value of liability warrants | -1 | -3,661 | -27 | 2 |
| Other income, net | 60 | 54 | 109 | 59 |
| Gain on extinguishment of debt | - | 24 | - | 429 |
| Loss before income tax provision | -2,622 | 1,481 | -1,575 | -1,580 |
| Income tax expense | 8 | 7 | 6 | 15 |
| Net loss | -2,630 | 1,474 | -1,581 | -1,595 |
| Net income (loss) available to common stockholders, basic | - | - | -1,581 | -1,595 |
| Earnings per share, basic | -2.25 | 18.98 | -3.11 | -0.06 |
| Earnings per share, diluted | -2.25 | 18.98 | -3.11 | -0.06 |
| Weighted average number of shares outstanding, basic | 1,168,759 | 77,668 | 508,851 | 25,222,443 |
| Weighted average number of shares outstanding, diluted | 1,168,759 | 77,668 | 508,851 | 25,222,443 |